Cloning humans is technically possible. It's curious no one has tried

Seven-month-oldDollyposesforphotographsin1997attheUniversityofEdinburgh'sRoslinInstitute,whereshewas NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn




focus

author：leisure time    Page View：4533
The Amgen booth at ESMO in Madrid.
The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

advertisement

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： The strategy behind pharma's lawsuits over drug pricing reform
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum